Extract
We read with great interest the study investigating the association between immunosuppressant and the outcome of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection [1]. They found that the prior use of immunosuppressant would be associated with a significantly increased risk of death (adjusted relative risk (aRR) 1.56, 95% CI 1.10–2.22) which was mainly driven by exposure to systemic glucocorticoids (aRR 2.38, 95% CI 1.72–3.30). Overall, it is a well-designed study; however, we have three concerns about the findings of this study.
Abstract
Immunosuppressants and underlying diseases could affect the outcome of patients of COVID-19, and this requires further analysis https://bit.ly/3A6rSeJ
Footnotes
Conflict of interest: C-K. Hsu has nothing to disclose. C-C. Lai has nothing to disclose.
- Received April 19, 2022.
- Accepted June 18, 2022.
- Copyright ©The authors 2022. For reproduction rights and permissions contact permissions{at}ersnet.org
LIBRARY USERS
Log in through your institution
Purchase access
